Increasing plasma neopterin and persistent plasma endothelin during follow-up after acute cerebral ischemia

Angiology

Volumn 50, Issue 1, 1999, Pages 1-8

  Anwaar, Ibrahim ^a   Gottsater A ^a   Lindgarde F ^a   Mattiasson, I ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN 1; NEOPTERIN;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BRAIN INFARCTION; BRAIN ISCHEMIA; CHRONIC INFLAMMATION; DRUG BLOOD LEVEL; FEMALE; HUMAN; INFLAMMATION; MACROPHAGE ACTIVATION; MAJOR CLINICAL STUDY; MALE; TRANSIENT ISCHEMIC ATTACK;

EID: 0345471483     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/000331979905000101     Document Type: Article

References (34)

1. Mathew V, Hasdai D, Lerman A: The role of endothelin in coronary atherosclerosis. Mayo Clin Proc 71:769-777, 1996.
2. Kojima S, Icho T, Kajiwara Y, et al: Neopterin as an endogenous antioxidant. FEBS Letters 304:163-166, 1992.
3. Tatzber F, Rabl H, Koriska K, et al: Elevated serum neopterin levels in atherosclerosis. Atherosclerosis 89:203-208, 1991.
4. Fuchs D, Hausen A, Reibnegger G, et al: Neopterin as a marker for activated cell-mediated immunity. Application in HIV infection. Immunol Today 9:150-155, 1988.
5. Huber C, Batchelor JR, Fuchs D, et al: Immune-response associated production of neopterin. Release from macrophages primarily under control of interferon gamma. J Exp Med 160:310-316, 1984.
6. Frederikson S, Eneroth P, Link H: Intrathecal production of neopterin in aseptic meningo-encephalitis and multiple sclerosis. Clin Exp Immunol 67:76, 1987.
7. Lerman A, Holms DR, Bell MR, et al: Endothelin in coronary endothelial dysfunction and early atherosclerosis in humans. Circulation 92:2426-2431, 1995.
8. Inoue A, Yanagisawa M, Kimura S, et al: The human endothelin family: Three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA 86:2863-2867, 1989.
9. Yanagisawa M, Kurihara H, Kimura S, et al: A novel potent vasoconstrictor produced by vascular endothelial cells. Nature 332:411-415, 1988.
10. Lüscher TF, Oemar BS, Boulanger CM, et al: Molecular and cellular biology of endothelin and its receptors. Part I. Part II. J Hypertens 11:7-11;121-126, 1993.
11. Lerman A, Hildebrand FL Jr, Margulies KB, et al: Endothelin: A new cardiovascular regulatory peptide. Mayo Clin Proc 65:1441-1445, 1990.
12. Ilan Z, Fleminger G, Djaldetti R, et al: Increased plasma endothelin-1 in acute ischemic stroke. Stroke 23:1014-1016, 1992.
13. Lerman A, Edwards BS, Hallett JW, et al: Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 325:997-1001, 1991.
14. Clozel M, Kuhn H, Hefti F, et al: Endothelial dysfunction and subendothelial monocyte-macrophages in hypertension. Effect of angiotensin converting enzyme inhibition. Hypertension 18:132-141, 1991.
15. Anwaar I, Gottsäter A, Ohlsson K, et al: Increasing levels of leukocyte derived inflammatory mediators in plasma and cAMP in platelets during follow-up after acute cerebral ischemia. Cerebrovasc Dis 1998 (in press).
16. Ridker PM, Cushman M, Stampfer MJ, et al: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336:973-979, 1997.
17. Huber C, Fuchs D, Niederwiesser D, et al: Neopterin as a new biochemical marker for cell mediated immune response. Klin Wochenschr 62:103, 1984.
18. Battistini B, D'Orleans JP, Sirois P: Biology of disease. Endothelins: Circulating plasma levels and presence in other biological fluids. Lab Invest 68:600-628, 1993.
19. Anwaar I, Gottsäter A, Hedblad B, et al: Endothelial derived vasoactive factors and leukocyte derived inflammatory mediators in subjects with asymptomatic atherosclerosis. Angiology 1998 (in press).
20. Estrada V, Tellez MJ, Moya J, et al: High plasma levels of endothelin-1 and atrial natriuretic peptide in patients with acute ischemic stroke. Am J Hypertens 7:1085-1089, 1994.
21. Yasuda M, Kohno M, Tahara A, et al: Circulating immunoreactive endothelin in ischemic heart disease. Am Heart J 119:801-806, 1990.
22. Ray SG, McMurray JJ, Morton JJ, et al: Circulating endothelin in acute ischemic syndromes. Br Heart J 67:383-386, 1992.
23. Miyauchi T, Yanagisawa M, Tomizawa T, et al: Increased plasma concentration of endothelin-1 and big endothelin-1 in acute myocardial infarction [letter]. Lancet 2:53-54, 1989.
24. Wei CM, Lerman A, Rodeheffer RJ, et al: Endothelin in human congestive heart failure. Circulation 89:1580-1586, 1994.
25. Rodeheffer RJ, Lerman A, Heublein DM, et al: Increased plasma concentrations of endothelin in congestive heart failure in humans. Mayo Clin Proc 67:719-724, 1992.
26. Kiowski W, Sutsch G, Hunziker P, et al: Evidence for endothelin-1 mediated vasoconstriction in severe chronic heart failure. Lancet 346:732-736, 1995.
27. Davenport AP, Ashby MJ, Easton P, et al: A sensitive radioimmunoassay measuring endothelin like immunoreactivity in human plasma: Comparison of levels in patients with essential hypertension and normotensive control subjects. Clin Sci 78:261-264, 1990.
28. Schiffrin EL, Thibault G: Plasma endothelin in human essential hypertension. Am J Hypertens 4:303-308, 1991.
29. Naruse M, Kaana M, Hifumi S, et al: Plasma immunoreactive endothelin, but not thrombomodulin, is increased in patients with essential hypertension and ischemic heart disease. J Cardiovasc Pharmacol 17:S471-474, 1991.
30. Saito Y, Nakao K, Mukoyama M, et al: Increased plasma endothelin level in patients with essential hypertension. N Engl J Med 322:205, 1990.
31. Diamondstone LS, Tollerud DJ, Fuchs D, et al: Factors influencing serum neopterin and beta2-microglobulin levels in a healthy diverse population. J Clin Immunol 14:368-374, 1994.
32. Miyauchi T, Yanagisawa M, Iida K, et al: Age- and sex-related variation of plasma endothelin-1 concentration in normal and hypertensive subjects. Am Heart J 123:1092-1093, 1992.
33. Reibnegger G, Huber LA, Jürgens G, et al: Approach to define normal ageing in man. Immune function, serum lipids, lipoproteins and neopterin levels. Mech Ageing Dev 46:67, 1988.
34. Ehrenreich H, Anderson RW, Fox CH, et al: Endothelin, peptides with potent vasoconstrictive properties, are produced by human macrophages. J Exp Med 172:1741-1748, 1990.